IRF评估新型冠状病毒肺炎患者死亡风险的价值

目的 探讨未成熟网织红细胞比率(IRF)在预测新型冠状病毒肺炎(COVID-19)患者死亡风险中的价值.方法 选取该院2020年1月23日至3月31日确诊的108例COVID-19患者为病例组,其中生存患者88例,死亡患者20例,并以同期进行体检的57例健康者为健康对照组.收集患者的病例资料,比较生存和死亡患者、COV...

The value of IRF in assessing mortality risk in COVID-19 patients

Objective To investigate the value of immature reticulocyte ratio(IRF)in predicting the risk of death in Corona Virus Disease 2019(COVID-19)patients.Methods A total of 108 COVID-19 patients diagnosed in the hospital from January 23 to March 31,2020 were selected as the case group,including 88 surviving patients and 20 dead patients.At the same time,57 healthy people were selected as control group.Information of cases were collected,the determination of reticulocyte absolute value(Ret#),equipment operation instruction,reticulocyte percentage(Ret%),high intensity of fluorescent reticulocyte(HFR),middle intensity of fluorescent reticulocyte(MFR),low intensity of fluorescent reticulocyte(LFR)and IRF were compared between survival and death patients,as well as between COVID-19 patients with different clinical types.The diagnostic value of IRF in the risk of death of COVID-19 was evaluated by receiver operating characteristic curve(ROC curve)and area under curve(AUC).Results The IRF level of case group was significantly higher than that of the control group(P<0.05).IRF level in the death group was significantly higher than that in the survival group(P<0.05).The AUC of IRF in predicting the death risk of COVID-19 was 0.774(95%CI:0.66-0.89).When the cut-off value of IRF was 7.90%in predicting the death risk of COVID-19,the sensitivity was 80.0%and specificity was 73.6%.Conclusion IRF level is a good predictor of mortality risk in COVID-19 patients.